WUSTL - Washington University in St. Louis
Welcome,         Profile    Billing    Logout  
 14 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vij, Ravi
NCT02253316: Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Active, not recruiting
2
236
US
Ixazomib, [14C]-ixazomib, [14C]-MLN9708, Lenalidomide, Revlimid, Dexamethasone, Aeroseb-Dex, Alba-Dex, Decaderm, Decadrol, Decadron, Decasone R.p., Decaspray, Deenar, Deronil, Dex-4, Dexace, Dexameth, Dezone, Gammacorten, Hexadrol, Maxidex, Sk-Dexamethasone
Washington University School of Medicine, Millennium Pharmaceuticals, Inc., Multiple Myeloma Research Consortium
Multiple Myeloma
02/20
08/25
CA204-225, NCT03030261: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Active, not recruiting
2
25
Canada, US
Elotuzumab, Empliciti, Pomalidomide, Pomalyst, Dexamethasone, Decadron
Washington University School of Medicine, Bristol-Myers Squibb, Celgene
Multiple Myeloma in Relapse
09/22
09/27
NCT06483100: Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

Recruiting
2
65
US
Elrantamab, clonoSEQ
Washington University School of Medicine, National Comprehensive Cancer Network, Pfizer, Rapid Novor
Multiple Myeloma
12/31
12/31
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
07/26
07/26
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Withdrawn
2
48
NA
Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis
Washington University School of Medicine
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
09/26
07/28
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Withdrawn
2
35
NA
Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron
Washington University School of Medicine, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma-Associated Amyloidosis
01/27
01/27
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Active, not recruiting
2
17
US
Duvelisib, Copiktra, Peripheral blood draw
Washington University School of Medicine, SecuraBio
T-Cell Lymphoma
07/26
07/26
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Active, not recruiting
2
107
US
Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology
Acute Myeloid Leukemia
07/29
07/29
MyDRUG, NCT03732703: Myeloma-Developing Regimens Using Genomics

Checkmark Data from MyDRUG study for MM at ASH 2022
Dec 2022 - Dec 2022: Data from MyDRUG study for MM at ASH 2022
Recruiting
1/2
228
US
Abemaciclib, dexamethasone, ixazomib, pomalidomide, abemaciclib: Verzenio, LY2835219, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst, Enasidenib, dexamethasone, ixazomib, pomalidomide, enasidenib: AG221, IDHIFA, Cobimetinib, dexamethasone, ixazomib, pomalidomide, cobimetinib: Cotellic, GDC-0973, RG7420, Erdafitinib, dexamethasone, ixazomib, pomalidomide, erdafitinib: G-024, JNJ-42756493, JNJ-493, Venetoclax, dexamethasone, ixazomib, pomalidomide, venetoclax: Venclexta: ABT-199, Daratumumab, dexamethasone, ixazomib, pomalidomide, daratumumab: Darzalex, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin: BLENREP, GSK2857916, Selinexor, dexamethasone, ixazomib, pomalidomide, Selinexor: XPOVIO
Multiple Myeloma Research Consortium, AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Janssen, LP, Takeda, GlaxoSmithKline, Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
02/22
02/24
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Active, not recruiting
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
12/23
12/24
NCT03068819: Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
110
US
CIML NK Cell Infusion, CD3+ T Cell Product Infusion
Washington University School of Medicine, National Cancer Institute (NCI), Wugen, Inc., Children's Discovery Institute
Acute Myeloid Leukemia
10/28
10/28
NCT04912427: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Terminated
1
1
US
Isatuximab, Sarclisa, Bortezomib, Velcade, Dexamethasone
Washington University School of Medicine, Sanofi
Multiple Myeloma
12/22
01/24
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

Terminated
1
4
US
ApoGraft
Washington University School of Medicine, Cellect Biotechnology
Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant
12/22
12/22
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Hourglass Apr 2020 - Jun 2020 : From trial in combination with bendamustine for penta-refractory multiple myeloma
Terminated
1
15
US
Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol
Washington University School of Medicine, Sanofi
Multiple Myeloma
03/23
03/24
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Completed
1
55
US
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
04/24
05/24
NCT06185751: Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Recruiting
1
25
US
WS-CART-CS1, Lymphodepleting chemotherapy
Washington University School of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research
Multiple Myeloma
08/29
08/40
NCT06547112: A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

Recruiting
1
20
US
Motixafortide, BL-8040, G-CSF
Washington University School of Medicine, BioLineRx, Ltd.
Multiple Myeloma
01/26
01/26
NCT03804424: 64Cu-LLP2A for Imaging Multiple Myeloma

Terminated
1
10
US
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, ECG, PET/CT
Washington University School of Medicine
Multiple Myeloma
10/21
10/21
NCT06623630: Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

Recruiting
1
12
US
Cyclophosphamide, Ciltacabtagene Autoleucel, Carvykti, cilta-cel, Total body irradiation, TBI
Washington University School of Medicine, American Cancer Society, Inc., Cures Within Reach
Multiple Myeloma
04/26
03/27
NCT06636175: 64Cu-LLP2A for Imaging Hematologic Malignancies

Not yet recruiting
1
42
US
64Cu-LLP2A, PET/CT
Washington University School of Medicine
Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
02/27
02/27
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Recruiting
1
49
US
Ruxolitinib, Jakafi
Washington University School of Medicine, Incyte Corporation
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
09/26
12/26
NCT06340646: Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Recruiting
N/A
990
US
Return of Genetic Results: Biomarker information from cancer cells, Return of Genetic Results: Inherited mutations related to cancer, Return of Genetic Results: Inherited mutations related to other medical issues
Washington University School of Medicine, National Cancer Institute (NCI), The Foundation for Barnes-Jewish Hospital
Cholangiocarcinoma, Multiple Myeloma, Colon Cancer, Rectal Cancer
01/27
01/27
NCT02611180: Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Recruiting
N/A
50
US
Skin punch biopsy, Peripheral blood draw
Washington University School of Medicine
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
04/25
04/25
NCT04545333: The clonoSEQ® Watch Registry

Terminated
N/A
465
US
clonoSEQ Assay
Adaptive Biotechnologies
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
10/23
10/23
NCT04263181: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Recruiting
N/A
165
US
Peripheral blood draw, Bone marrow aspirate, Buccal swab
Washington University School of Medicine, Notable Labs
Acute Myeloid Leukemia, Myelodysplastic Syndromes
01/25
01/25

Download Options